Carbon-11-Labeled Methionine PET/CT in Patients With FDG-Occult Multiple Myeloma: A Prospective Pilot Study.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 36382911.
- Also identified by DOI 10.2214/AJR.22.28560.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In a pilot study (ClinicalTrials.gov NCT02646085), seven patients with treated multiple myeloma and negative FDG PET/CT underwent amino acid imaging with <sup>11</sup>C-methionine PET/CT. In five participants, <sup>11</sup>C-methionine PET/CT showed focal uptake corresponding with lytic lesions; two to 18 lesions were found (SUV<sub>max</sub>, 2.8-6.4). Findings indicated a potential role for <sup>11</sup>C-methionine PET/CT in detecting residual disease after negative FDG PET/CT, thereby guiding further treatment.
Medical subject headings
- Positron Emission Tomography Computed Tomography
- Multiple Myeloma